Table 1 Ongoing clinical trials evaluating neoadjuvant immunotherapy in HCC

NCT04930315

Camrelizumab + apatinib

Phase 2, open label

BCLC B/C, or CNLC IIa-IIIb; technically resectable

1-year tumor recurrence-free rate

NCT03630640

Nivolumab

Phase 2, open label

BCLC A; receiving electroporation

2-year RFS

NCT04727307 (AB-LATE02)

Atezolizumab

Phase 2, open label

Percutaneous Radiofrequency

2-year RFS

NCT04615143

Atezolizumab;

Phase 2, single arm

Resectable recurrent HCC

Pathological response rate

NCT04658147

Nivolumab With or Without Relatlimab

Phase 1

Potentially Resectable HCC

No. of patients who complete treatment and surgery

NCT03916627

Cemiplimab

Phase 2

Resectable HCC

Significant tumor necrosis